Neuroscience in Denmark

Back to overview

General information

Name (center, department, group or other)
Bach Group, Dept. Drug Design and Pharmacology, University of Copenhagen
Contact name
Anders Bach
Contact email
Contact title
Assistant Professor
25. January 2016
(Last edited: 25. January 2016)

Brief description of research activities

In our group we focus on medicinal chemistry and brain proteins. Our goal is to develop biological active small-molecule inhibitors against CNS proteins involved in excitotoxicity and oxidative stress. We evaluate the druggability of selected targets and aim at developing new high-quality chemical probes useful for pharmacological studies and for identifying new therapeutic principles against ischemic stroke and related diseases.

Fragment-based drug discovery (FBDD) is a core theme of our research. We screen our library of >2500 fragments (i.e. small substructures of druglike molecules) using very sensitive biophysical methods (SPR and ligand-based NMR) and biochemical assays. Promising hits are optimized into lead molecules by medicinal chemistry, biostructural studies and pharmacology.


Medicinal Chemistry, Fragment-based drug discovery, Small molecules, Multi-target inhibitors, Surface Plasmon Resonance (SPR), Ligand-based NMR, Ischemic Stroke, Keap1, NADPH oxidase, PSD-95

Research tools and techniques

Medicinal Chemistry, Fragment-based drug discovery, Fragment Screening, Protein expression, Surface Plasmon Resonance (SPR)

Scientific Personnel

No of Associate Professors/Postdocs: 3
No of PhD students: 1
Other: 1

Key references from within the last 5 years

Bach, A.*; Pedersen, T. B.; Strømgaard, K. Design and synthesis of triazole-based peptidomimetics of a PSD-95 PDZ domain inhibitor. Med. Chem. Comm. 2016, in press. (*Corresponding).

Bach, A.*; Pizzirani, D.*; Realini, N.; Vozella, V.; Russo, D.; Penna, I.; Melzig, L.; Scarpelli, R.; Piomelli, D. Benzoxazolone carboxamides as potent acid ceramidase inhibitors: Synthesis and structure-activity relationship (SAR) studies. J. Med. Chem. 2015, 58, 9258–9272. (*Shared 1st)

Bach, A.*; Pedersen, S. W.; Dorr, L. A.; Vallon, G.; Ripoche, I.; Ducki, S.; Lian, L.-Y*. Biochemical investigations of the mechanism of action of small molecules ZL006 and IC87201 as potential inhibitors of the nNOS-PDZ/PSD-95-PDZ interactions. Sci. Rep. 2015, 5, 12157. (*Corresponding).

Pizzirani, D.*; Bach, A.*; Realini, N.; Armirotti, A.; Mengatto, L.; Bauer, I.; Girotto, S.; Pagliuca, C.; De Vivo, M.; Summa, M.; Ribeiro, A.; Piomelli, D. Benzoxazolone Carboxamides: Potent and systemically active inhibitors of intracellular acid ceramidase. Angew. Chem. Int. Ed. 2015, 54, 485–489. (*Shared 1st)

Bach, A.*; Clausen, B. H.; Møller, M.; Vestergaard, B.; Chi, C. N.; Round, A.; Sørensen, P. L.; Nissen, K. B.; Kastrup, J. S.; Gajhede, M.; Jemth, P.; Kristensen, A. S.; Lundström, P.; Lambertsen, K. L.; Strømgaard, K.*. A high-affinity, dimeric inhibitor of PSD-95 bivalently interacts with PDZ1-2 and protects against ischemic brain damage. Proc. Natl. Acad. Sci. U. S. A. 2012, 109, 3317-3322. (*Corresponding).
Scherfigsvej 7
2100 Copenhagen Ø
Tel. +45 39 12 80 00
CVR-nr. 11 81 49 13
Nils Axelsen Ralf Hemmingsen Lauritz Holm-Nielsen Ralf Hemmingsen Jens Oddershede Jens Frederik Rehfeld Anders Bjørklund